The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
17-allylaminogeldanamycin in advanced medullary and differentiated thyroid carcinoma.
J. F. Moley
No relevant relationships to disclose
D. Adkins
No relevant relationships to disclose
K. C. Bible
No relevant relationships to disclose
A. M. Traynor
No relevant relationships to disclose
J. R. Molina
No relevant relationships to disclose
G. Colon-Otero
No relevant relationships to disclose
T. J. Pluard
No relevant relationships to disclose
M. H. Shah
Research Funding - Bayer; Daiichi Sankyo; Eisai; Exelixis
R. Suresh
No relevant relationships to disclose
C. Erlichman
Research Funding - Bristol-Myers Squibb
S. P. Ivy
No relevant relationships to disclose
V. Suman
No relevant relationships to disclose
S. M. Geyer
No relevant relationships to disclose
P. M. Fracasso
No relevant relationships to disclose
M. S. Cohen
No relevant relationships to disclose
H. Tang
No relevant relationships to disclose
E. Fialkowski
No relevant relationships to disclose
A. Traugott
No relevant relationships to disclose
R. C. Smallridge
No relevant relationships to disclose